Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data

Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data

Our aim was to evaluate real-world time on treatment (rwToT), overall and by <i>KRAS</i> mutation status, with first-line pembrolizumab monotherapy for advanced non-small cell lung cancer (NSCLC) in real-world oncology practice in the US. rwToT is a readily available, intermediate-range...

Full description

Bibliographic Details
Main Authors: Vamsidhar Velcheti, Xiaohan Hu, Yeran Li, Hazem El-Osta, M. Catherine Pietanza, Thomas Burke
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cancers
Subjects:
advanced NSCLC
<i>KRAS</i> mutation
lines of therapy
overall survival
pembrolizumab
treatment duration
Online Access:https://www.mdpi.com/2072-6694/14/4/1041

Similar Items

Similar Items